ly007
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 25, 2021 (NCT06364852)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- B-lymphocyte antigen CD20Immunity, passive
MS4A1 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06279611 | Phase 1 | Dec 25, 2021 | Jiao Tong University, Nanjing Medical University, Shanghai Longyao Biotechnology Inc., Ltd. |
| NCT06364852 | Phase 1 | Dec 25, 2021 | Jiao Tong University, Nanjing Medical University, Shanghai Longyao Biotechnology Inc., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiao Tong University | Academic/Hospital | 2 | 1 | 1 | 2021 |
| Nanjing Medical University | Academic/Hospital | 2 | 0 | 1 | 2021 |
| Shanghai Longyao Biotechnology Inc., Ltd. | Government | 2 | 1 | 1 | 2021 |
3 organizations
Page 1 / 1